USD 12.17
↓ -0.28 (-2.25%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| MLYS | -2.2 | -14.9 | -10.4 | 33.3 | -6.8 | 70.2 | -34.0 | -34.0 | -34.0 | -34.0 |
| S&P 500 | -0.6 | -0.5 | 1.5 | 9.1 | 13.4 | 32.3 | 27.0 | 92.1 | 191.7 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | MLYS |
| name | Mineralys Therapeutics, Inc. |
| price | 12.17 |
| changes percentage | -2.249 |
| change | -0.28 |
| day low | 12.09 |
| day high | 12.83 |
| year high | 16.905 |
| year low | 5.85 |
| market cap | 605173610 |
| price avg 50 | 12.9894 |
| price avg 200 | 12.86525 |
| exchange | NASDAQ |
| volume | 197636 |
| avg volume | 171498 |
| open | 12.45 |
| previous close | 12.45 |
| eps | -2.76 |
| pe | -4.41 |
| earnings announcement | 2024-11-11T05:00:00.000+0000 |
| shares outstanding | 49726673 |
| timestamp | 2024-11-14 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001933414 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | 0 | NaN |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 70361000 | 26250000 | 168.04 |
| operating expenses | 84657000 | 31479000 | 168.93 |
| interest income | 12756000 | 1676000 | 661.10 |
| interest expense | 0 | 1676000 | -100.00 |
| ebitda | -84657000 | -31479000 | -168.93 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -84657000 | -31479000 | -168.93 |
| operating income ratio | 0 | 0 | NaN |
| net income | -71898000 | -29799000 | -141.28 |
| net income ratio | 0 | 0 | NaN |
| eps | -1.99 | -0.73 | -172.60 |
Research and Development (R&D) Expenses: R&D Expenses increased to 70 million in 2023 from 26 million in 2022 representing a change of 168.04%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -85 million in 2023 from -31 million in 2022 representing a change of -168.93%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -85 million in 2023 from -31 million in 2022 representing a change of -168.93%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -72 million in 2023 from -30 million in 2022 representing a change of -141.28%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 85 million in 2023 from 31 million in 2022 representing a change of 168.93%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -1.99 in 2023 from -1.99 in 2022 representing a change of -172.6%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001933414 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -9000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 53985000 | 39273000 | 37.46 |
| operating expenses | 60106000 | 45168000 | 33.07 |
| interest income | 0 | 4152000 | -100.00 |
| interest expense | 0 | 0 | NaN |
| ebitda | -60106000 | -45159000 | -33.10 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -60106000 | -45168000 | -33.07 |
| operating income ratio | 0 | 0 | NaN |
| net income | -56342000 | -41014000 | -37.37 |
| net income ratio | 0 | 0 | NaN |
| eps | -1.13 | -0.83 | -36.14 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 54 million in 2024Q3 from 39 million in 2024Q2 representing a change of 37.46%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -60 million in 2024Q3 from -45 million in 2024Q2 representing a change of -33.1%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -60 million in 2024Q3 from -45 million in 2024Q2 representing a change of -33.07%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -56 million in 2024Q3 from -41 million in 2024Q2 representing a change of -37.37%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 60 million in 2024Q3 from 45 million in 2024Q2 representing a change of 33.07%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -1.13 in 2024Q3 from -1.13 in 2024Q2 representing a change of -36.14%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001933414 | |||
| total assets | 251636000 | 114442000 | 119.88 |
| total liabilities | 10482000 | 166711000 | -93.71 |
| total equity | 241154000 | -52269000 | 561.37 |
| cash and cash equivalents | 49304000 | 87701000 | -43.78 |
| short term investments | 187263000 | 22409000 | 735.66 |
| long term investments | 2482000 | 0 | NaN |
| total current assets | 249103000 | 110110000 | 126.23 |
| total non current assets | 2533000 | 4332000 | -41.53 |
| total current liabilities | 10482000 | 8067000 | 29.94 |
| total non current liabilities | 0 | 158644000 | -100.00 |
| common stock | 4000 | 1000 | 300.00 |
| retained earnings | -124708000 | -52810000 | -136.14 |
| total debt | 0 | 0 | NaN |
Total Assets: Total Assets increased to 252 million in 2023 from 114 million in 2022 representing a change of 119.88%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 10 million in 2023 from 167 million in 2022 representing a change of -93.71%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 241 million in 2023 from -52 million in 2022 representing a change of 561.37%. This indicates an increase in shareholders' equity.
Short Term Investments: Short Term Investments increased to 187 million in 2023 from 22 million in 2022 representing a change of 735.66%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 249 million in 2023 from 110 million in 2022 representing a change of 126.23%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 300.0%. This indicates an increase in ownership interest.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 49 million in 2023 from 88 million in 2022 representing a change of -43.78%. This indicates a decrease in available liquid assets.
Total Current Liabilities: Total Current Liabilities increased to 10 million in 2023 from 8 million in 2022 representing a change of 29.94%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -125 million in 2023 from -53 million in 2022 representing a change of -136.14%. This indicates an accumulated losses.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001933414 | |||
| total assets | 268253000 | 318492000 | -15.77 |
| total liabilities | 31321000 | 28397000 | 10.30 |
| total equity | 236932000 | 290095000 | -18.33 |
| cash and cash equivalents | 97274000 | 67856000 | 43.35 |
| short term investments | 0 | 243259000 | -100.00 |
| long term investments | 0 | 0 | NaN |
| total current assets | 267732000 | 318001000 | -15.81 |
| total non current assets | 521000 | 491000 | 6.11 |
| total current liabilities | 31321000 | 28397000 | 10.30 |
| total non current liabilities | 0 | 0 | NaN |
| common stock | 5000 | 5000 | 0.00 |
| retained earnings | -253572000 | -197230000 | -28.57 |
| total debt | 0 | 0 | NaN |
Total Assets: Total Assets decreased to 268 million in 2024Q3 from 318 million in 2024Q2 representing a change of -15.77%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 31 million in 2024Q3 from 28 million in 2024Q2 representing a change of 10.3%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 237 million in 2024Q3 from 290 million in 2024Q2 representing a change of -18.33%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 0 million in 2024Q3 from 243 million in 2024Q2 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 268 million in 2024Q3 from 318 million in 2024Q2 representing a change of -15.81%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 31 million in 2024Q3 from 28 million in 2024Q2 representing a change of 10.3%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -254 million in 2024Q3 from -197 million in 2024Q2 representing a change of -28.57%. This indicates an accumulated losses.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 97 million in 2024Q3 from 68 million in 2024Q2 representing a change of 43.35%. This indicates an increase in available liquid assets.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001933414 | |||
| net change in cash | -38397000 | 77039000 | -149.84 |
| operating cash flow | -81173000 | -29221000 | -177.79 |
| free cash flow | -81173000 | -29221000 | -177.79 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 0 | 0 | NaN |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 5060000 | 455000 | 1012.09 |
| accounts payables | 0 | 3012000 | -100.00 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | -160472000 | -21759000 | -637.50 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 202990000 | 0 | NaN |
| common stock repurchased | 0 | -1629000 | 100.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 203248000 | 128019000 | 58.76 |
| cash at end of period | 49304000 | 87701000 | -43.78 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 87701000 | 10662000 | 722.56 |
Net Change in Cash: Net Change in Cash decreased to -38 million in 2023 from 77 million in 2022 representing a change of -149.84%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -81 million in 2023 from -29 million in 2022 representing a change of -177.79%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -81 million in 2023 from -29 million in 2022 representing a change of -177.79%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 5 million in 2023 from 0 million in 2022 representing a change of 1012.09%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023 from 3 million in 2022 representing a change of -100.0%. This indicates that the company has reduced its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001933414 | |||
| operating cash flow | -50186000 | -30146000 | -66.48 |
| free cash flow | -50223000 | -30146000 | -66.60 |
| capital expenditure | -37000 | 0 | NaN |
| depreciation and amortization | 11000 | 9000 | 22.22 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 6008128 | 2872 | 209096.66 |
| accounts receivables | -184000 | 184000 | -200.00 |
| accounts payables | 12436000 | 0 | NaN |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -37000 | 0 | NaN |
| net cash used for investing activites | 79605000 | 7736000 | 929.02 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 6000 | -60000 | 110.00 |
| common stock repurchased | 138000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -1000 | -152000 | 99.34 |
| net change in cash | 29418000 | -22562000 | 230.39 |
| cash at end of period | 97274000 | 67856000 | 43.35 |
| cash at beginning of period | 67856000 | 90418000 | -24.95 |
Net Change in Cash: Net Change in Cash increased to 29 million in 2024Q3 from -23 million in 2024Q2 representing a change of 230.39%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -200.0%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -50 million in 2024Q3 from -30 million in 2024Q2 representing a change of -66.48%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -50 million in 2024Q3 from -30 million in 2024Q2 representing a change of -66.6%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 6 million in 2024Q3 from 0 million in 2024Q2 representing a change of 209096.66%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 12 million in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This indicates that the company has increased its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -1.99 | -0.73 | -172.40 |
| operating cash flow per share | -2.24 | -0.72 | -213.63 |
| free cash flow per share | -2.24 | -0.72 | -213.63 |
| cash per share | 6.54 | 2.7 | 142.56 |
| book value per share | 6.66 | -1.28 | 620.89 |
| tangible book value per share | 6.66 | -1.28 | 620.89 |
| shareholders equity per share | 6.66 | -1.28 | 620.89 |
| interest debt per share | 0 | 0.04 | -100.00 |
| market cap | 311216800 | 753396681.32 | -58.69 |
| enterprise value | 261912800 | 665695681.32 | -60.66 |
| pe ratio | -4.33 | -25.28 | 82.88 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -3.83 | -25.78 | 85.13 |
| pfcf ratio | -3.83 | -25.78 | 85.13 |
| pb ratio | 1.29 | -14.41 | 108.95 |
| ptb ratio | 1.29 | -14.41 | 108.95 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -3.09 | -21.15 | 85.37 |
| ev to operating cash flow | -3.23 | -22.78 | 85.84 |
| ev to free cash flow | -3.23 | -22.78 | 85.84 |
| earnings yield | -0.23 | -0.04 | -484.08 |
| free cash flow yield | -0.26 | -0.04 | -572.48 |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | 0.58 | 2.79 | -79.10 |
| current ratio | 23.76 | 13.65 | 74.11 |
| interest coverage | 0 | -18.78 | 100.00 |
| income quality | 1.13 | 0.98 | 15.13 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 17.26 | 4.58 | 276.69 |
| roic | -0.35 | 0.56 | -162.27 |
| return on tangible assets | -0.29 | -0.26 | -9.73 |
| graham net net | 6.25 | -1.39 | 550.97 |
| working capital | 238621000 | 102043000 | 133.84 |
| tangible asset value | 241154000 | -52269000 | 561.37 |
| net current asset value | 238621000 | -56601000 | 521.58 |
| invested capital | 238621000 | 102043000 | 133.84 |
| average receivables | 0 | 0 | NaN |
| average payables | 1254000 | 1335000 | -6.07 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0 | NaN |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.3 | 0.57 | -152.30 |
| capex per share | 0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -0.30 on 2023-12-31 from 0.57 on 2022-12-31, representing a change of -152.30%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 23.76 on 2023-12-31 from 13.65 on 2022-12-31, representing a change of 74.11%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -4.33 on 2023-12-31 from -25.28 on 2022-12-31, representing a change of 82.88%. Indicating an increase in the relative valuation of the company's stock.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| MLYS | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -1.13 | -0.83 | -36.11 |
| operating cash flow per share | -1.01 | -0.61 | -64.94 |
| free cash flow per share | -1.01 | -0.61 | -65.06 |
| cash per share | 1.95 | 6.3 | -69.02 |
| book value per share | 4.76 | 5.88 | -19.08 |
| tangible book value per share | 4.76 | 5.88 | -19.08 |
| shareholders equity per share | 4.76 | 5.88 | -19.08 |
| interest debt per share | 0 | 0 | NaN |
| market cap | 603261902.46 | 600666012.79 | 0.43 |
| enterprise value | 505987902.46 | 532810012.79 | -5.03 |
| pe ratio | -2.68 | -3.66 | 26.89 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -12.02 | -19.93 | 39.67 |
| pfcf ratio | -12.01 | -19.93 | 39.72 |
| pb ratio | 2.55 | 2.07 | 22.97 |
| ptb ratio | 2.55 | 2.07 | 22.97 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -8.42 | -11.8 | 28.65 |
| ev to operating cash flow | -10.08 | -17.67 | 42.96 |
| ev to free cash flow | -10.07 | -17.67 | 43.00 |
| earnings yield | -0.09 | -0.07 | -36.78 |
| free cash flow yield | -0.08 | -0.05 | -65.88 |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | 1.62 | 1.5 | 7.70 |
| current ratio | 8.55 | 11.2 | -23.67 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.89 | 0.74 | 21.19 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 3.36 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 11.0 | 10.48 | 4.95 |
| roic | -0.25 | -0.16 | -62.93 |
| return on tangible assets | -0.21 | -0.13 | -63.10 |
| graham net net | 1.32 | 5.73 | -76.89 |
| working capital | 236411000 | 289604000 | -18.37 |
| tangible asset value | 236932000 | 290095000 | -18.33 |
| net current asset value | 236411000 | 289604000 | -18.37 |
| invested capital | 236480000 | 289646000 | -18.36 |
| average receivables | 0 | 0 | NaN |
| average payables | 2406500 | 2984000 | -19.35 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 17070 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.01 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.24 | -0.14 | -68.20 |
| capex per share | 0.0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -0.24 on 2024-09-30 Q3 from -0.14 on 2024-06-30 Q2, representing a change of -68.20%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 8.55 on 2024-09-30 Q3 from 11.20 on 2024-06-30 Q2, representing a change of -23.67%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -2.68 on 2024-09-30 Q3 from -3.66 on 2024-06-30 Q2, representing a change of 26.89%. Indicating an increase in the relative valuation of the company's stock.
Negative Sentiment: Discounted Cash Flow value is 1.36 which is lower than current price 12.17, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-11 22:00:07
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Richard Law - Goldman Sachs Annabel Samimy - Stifel Rami Katkhuda - LifeSci Capital Matthew Caufield - H.C. Wainright Operator Greetings.
Sentiment: Neutral
Publish Date: 2024-11-11 16:05:00
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
Sentiment: Positive
Publish Date: 2024-11-05 16:05:00
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences.
Sentiment: Positive
Publish Date: 2024-11-04 16:05:00
RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024.
Sentiment: Negative
Publish Date: 2024-10-21 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-20 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-19 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-18 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-17 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-16 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-15 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-14 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-13 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-12 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-11 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-10 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-09 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-08 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-07 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sentiment: Negative
Publish Date: 2024-10-06 11:00:00
LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
